-$0.33 EPS Expected for Minerva Surgical, Inc. (NASDAQ:UTRS) This Quarter

Equities research analysts forecast that Minerva Surgical, Inc. (NASDAQ:UTRSGet Rating) will announce ($0.33) earnings per share for the current fiscal quarter, Zacks reports. Three analysts have provided estimates for Minerva Surgical’s earnings, with the highest EPS estimate coming in at ($0.30) and the lowest estimate coming in at ($0.36). The firm is scheduled to issue its next earnings results on Monday, January 1st.

According to Zacks, analysts expect that Minerva Surgical will report full-year earnings of ($1.24) per share for the current financial year, with EPS estimates ranging from ($1.44) to ($1.13). For the next year, analysts anticipate that the company will post earnings of ($1.00) per share, with EPS estimates ranging from ($1.05) to ($0.92). Zacks Investment Research’s EPS averages are an average based on a survey of research analysts that that provide coverage for Minerva Surgical.

Minerva Surgical (NASDAQ:UTRSGet Rating) last released its quarterly earnings data on Wednesday, May 11th. The company reported ($0.38) earnings per share for the quarter, missing the consensus estimate of ($0.31) by ($0.07).

UTRS has been the subject of a number of research analyst reports. Piper Sandler lowered their target price on Minerva Surgical from $12.00 to $6.00 in a research note on Thursday, May 12th. Zacks Investment Research cut Minerva Surgical from a “hold” rating to a “sell” rating in a research note on Wednesday. One research analyst has rated the stock with a sell rating and four have given a buy rating to the company. According to MarketBeat.com, Minerva Surgical currently has an average rating of “Buy” and an average target price of $10.50.

UTRS opened at $2.35 on Thursday. The company has a debt-to-equity ratio of 1.13, a quick ratio of 1.72 and a current ratio of 2.32. The business has a 50 day moving average of $3.84 and a 200-day moving average of $5.21. Minerva Surgical has a 52 week low of $1.61 and a 52 week high of $10.37.

A number of large investors have recently made changes to their positions in the business. Virtu Financial LLC purchased a new position in Minerva Surgical during the fourth quarter valued at $54,000. Renaissance Technologies LLC bought a new stake in shares of Minerva Surgical in the 4th quarter worth $78,000. BlackRock Inc. bought a new stake in shares of Minerva Surgical in the 4th quarter worth $88,000. Millennium Management LLC bought a new stake in shares of Minerva Surgical in the 4th quarter worth $134,000. Finally, Ghisallo Capital Management LLC bought a new stake in shares of Minerva Surgical in the 4th quarter worth $386,000. Institutional investors and hedge funds own 69.55% of the company’s stock.

Minerva Surgical Company Profile (Get Rating)

Minerva Surgical, Inc, a commercial-stage medical technology company, develops, manufactures, and commercializes minimally invasive solutions to meet the uterine healthcare needs of women in the United States. The company offers Minerva ES Endometrial Ablation System and Genesys HTA Endometrial Ablation System, which are endometrial ablation devices; Symphion Tissue Removal System, a minimally invasive uterine tissue removal system to combine bladeless tissue resection and coagulation, continuous visualization, and intrauterine pressure monitoring; and Resectr Tissue Resection Device, a handheld surgical instrument to enable the hysteroscopic removal and diagnosis of endometrial polyps.

Featured Stories

Get a free copy of the Zacks research report on Minerva Surgical (UTRS)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Minerva Surgical (NASDAQ:UTRS)

Receive News & Ratings for Minerva Surgical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Minerva Surgical and related companies with MarketBeat.com's FREE daily email newsletter.